Kyowa Kirin Co., Ltd. (OTCMKTS:KYKOF – Get Free Report) rose 0.9% on Monday. The stock traded as high as $16.7730 and last traded at $16.45. Approximately 554 shares changed hands during mid-day trading, a decline of 94% from the average session volume of 8,608 shares. The stock had previously closed at $16.30.
Analyst Upgrades and Downgrades
Separately, Jefferies Financial Group cut Kyowa Kirin to a “hold” rating in a research note on Tuesday, September 8th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Kyowa Kirin currently has an average rating of “Reduce”.
Check Out Our Latest Research Report on KYKOF
Kyowa Kirin Trading Up 0.9%
About Kyowa Kirin
Kyowa Kirin Co., Ltd. is a Japan-based pharmaceutical company and a member of the Kirin Holdings group. The company researches, develops, manufactures and markets prescription medicines, with an emphasis on specialty therapies for conditions that often have significant unmet medical needs. Its focus areas include oncology, immunology, nephrology, neurology and rare diseases. Kyowa Kirin’s products include Crysvita (burosumab), a treatment for certain phosphate-wasting disorders, and Poteligeo (mogamulizumab), an antibody therapy used for specific blood cancers.
Recommended Stories
- Five stocks we like better than Kyowa Kirin
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Kyowa Kirin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyowa Kirin and related companies with MarketBeat.com's FREE daily email newsletter.
